Showing 6571-6580 of 10156 results for "".
- Altreno: Exclusive Size Available for Dermatologist Dispensinghttps://practicaldermatology.com/news/altreno-exclusive-size-available-for-dermatologist-dispensing/2460182/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- EADV News: Psoriasis Largely Undertreated, Travels with Anxietyhttps://practicaldermatology.com/news/eadv-news-psoriasis-largely-undertreated-travels-with-anxiety/2460175/Many psoriasis patients remain un- or undertreated, with an average diagnosis time of five years, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. In the study of 650 psoriasis patients in Germany, more than half of patients (56 percen
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- Electric Tech May Help Reverse Baldnesshttps://practicaldermatology.com/news/electric-tech-may-help-reverse-baldness/2460156/Reversing baldness could someday be as easy as wearing a hat, thanks to a noninvasive, low-cost hair-growth-stimulating technology developed by engineers at the University of Wisconsin–Madison. Xudong Wang, a professor of materials science and engineering at UW–Madison. and
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- Why Don't More Derms Use Lab-based Tools to ID Fungal Infections?https://practicaldermatology.com/news/why-dont-more-derms-use-lab-based-tools-to-id-fungal-infections/2460128/Fungal diagnostic preparations can assist the accurate diagnosis of cutaneous fungal infections. A survey from a team at the George Washington University (GW) identifies barriers that prevent their consistent use. The study is published in the
- Psoriasis Therapy Linked to Reduced Coronary Inflammationhttps://practicaldermatology.com/news/psoriasis-therapy-linked-to-reduced-coronary-inflammation/2460112/Anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat a
- Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugshttps://practicaldermatology.com/news/summer-aad-news-understanding-the-dermatologists-role-in-reducing-skin-related-side-effects-from-new-cancer-drugs/2460107/While a new wave of targeted therapies are helping patients fight cancer, they also produce side effects that can affect patients’ hair, skin and nails that can greatly impact patients’ quality of life and threaten their ability to continue treatment. “Approximat
- Summer AAD News: Hyperhidrosis Updatehttps://practicaldermatology.com/news/summer-aad-news-hyperhidrosis-update/2460106/At least 15 million people in the U.S. experience diminished quality of life due to hyperhidrosis, yet half of people with the condition delay treatment for 10 years or more, according to information presented at the 2019 American Academy of Dermatology Summer Meeting in New York City.